Qi Zhou

3.1k total citations · 2 hit papers
91 papers, 1.5k citations indexed

About

Qi Zhou is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Qi Zhou has authored 91 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 30 papers in Oncology and 22 papers in Cancer Research. Recurrent topics in Qi Zhou's work include Ovarian cancer diagnosis and treatment (13 papers), Cancer-related molecular mechanisms research (13 papers) and PARP inhibition in cancer therapy (10 papers). Qi Zhou is often cited by papers focused on Ovarian cancer diagnosis and treatment (13 papers), Cancer-related molecular mechanisms research (13 papers) and PARP inhibition in cancer therapy (10 papers). Qi Zhou collaborates with scholars based in China, United States and Singapore. Qi Zhou's co-authors include Xiao Zheng, Jingting Jiang, Lujun Chen, Bin Xu, Chen Wu, Wenwei Hu, Changping Wu, You Zhou, Qi Wang and Zhuojun Zheng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Qi Zhou

81 papers receiving 1.5k citations

Hit Papers

A novel protein encoded b... 2019 2026 2021 2023 2019 2025 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling
    2019 425 citations Qi Zhou et al. profile →
  2. Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy
    2025 20 citations Huan Song, Lin Chen et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qi Zhou China 21 1.0k 649 306 119 115 91 1.5k
Jing Yuan China 21 884 0.9× 347 0.5× 331 1.1× 182 1.5× 65 0.6× 51 1.4k
Lina Gu China 22 1.0k 1.0× 654 1.0× 274 0.9× 200 1.7× 71 0.6× 70 1.5k
Keqiang Zhang China 29 1.2k 1.2× 682 1.1× 456 1.5× 267 2.2× 205 1.8× 75 1.9k
Yan Ding China 16 648 0.6× 560 0.9× 348 1.1× 67 0.6× 86 0.7× 46 1.3k
Jiekai Yu China 21 789 0.8× 240 0.4× 255 0.8× 163 1.4× 99 0.9× 73 1.5k
Rong Ma China 25 1.0k 1.0× 798 1.2× 305 1.0× 125 1.1× 87 0.8× 71 1.6k
Denglong Wu China 24 805 0.8× 497 0.8× 152 0.5× 312 2.6× 172 1.5× 87 1.5k
Bingyin Shi China 25 1.1k 1.0× 355 0.5× 342 1.1× 232 1.9× 190 1.7× 87 1.9k
Jenq-Chang Lee Taiwan 18 758 0.7× 374 0.6× 242 0.8× 86 0.7× 66 0.6× 31 1.1k

Countries citing papers authored by Qi Zhou

Since Specialization
Citations

This map shows the geographic impact of Qi Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qi Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qi Zhou more than expected).

Fields of papers citing papers by Qi Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qi Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qi Zhou. The network helps show where Qi Zhou may publish in the future.

Co-authorship network of co-authors of Qi Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Qi Zhou. A scholar is included among the top collaborators of Qi Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qi Zhou. Qi Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Haixia, Jianqing Zhu, Dongling Zou, et al.. (2025). Multicenter study of ovarian cancer score for diagnosing ovarian cancer. Gynecologic Oncology. 193. 58–64. 1 indexed citations
2.
Song, Huan, Lin Chen, Guohong Wang, et al.. (2025). Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer Cell. 43(3). 503–518.e10. 20 indexed citations breakdown →
3.
4.
Bai, Yanfeng, et al.. (2024). Remote sensing ghost imaging based on Hadamard modulated Gaussian array beam. Optics Communications. 574. 131108–131108. 1 indexed citations
5.
Li, Zhihui, Qinlong Zheng, Keyan Yang, et al.. (2024). CD7 CART Therapy Bridging Allo-HSCT Remarkably Improves Long-Term DFS in Refractory/Relapsed T-ALL/LBL. Transplantation and Cellular Therapy. 31(2). 73.e1–73.e11. 1 indexed citations
6.
Yang, Meng, et al.. (2024). Bifidobacterium bifidum alleviates adenine-induced acute kidney injury in mice by improving intestinal barrier function. Food & Function. 15(15). 8030–8042. 5 indexed citations
7.
Shu, Jian, Ting Zhu, Yunchao Huang, et al.. (2024). 720MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study. Annals of Oncology. 35. S551–S551. 2 indexed citations
8.
Zhou, Qi, Xiaowen Hao, Yue Li, et al.. (2024). Endothelial Robo4 suppresses endothelial-to-mesenchymal transition induced by irradiation and improves hematopoietic reconstitution. Cell Death and Disease. 15(2). 159–159. 4 indexed citations
9.
Zhao, Pingping, et al.. (2024). Association of different obesity indexes with diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. Scientific Reports. 14(1). 21571–21571. 4 indexed citations
10.
Zhou, Yun, Yanling Feng, Jinjin Yu, et al.. (2024). QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial. Journal of Gynecologic Oncology. 35(6). e77–e77. 4 indexed citations
11.
Birrer, Michael J., Guiling Li, Mayu Yunokawa, et al.. (2024). Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure. JAMA Oncology. 10(9). 1204–1204. 11 indexed citations
12.
Jiang, Wei, Pengying Wang, Qi Zhou, et al.. (2023). Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine. Journal of Translational Medicine. 21(1). 885–885. 1 indexed citations
13.
14.
Liu, Jingshu, Jiangfeng Qiu, Zhi‐Qi Zhang, et al.. (2021). SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study. Cell & Bioscience. 11(1). 23–23. 30 indexed citations
15.
Wang, Yingmei, Shiqian Zhang, Lihui Wei, et al.. (2020). Recommendations on management of gynecological malignancies during the COVID-19 pandemic: perspectives from Chinese gynecological oncologists. Journal of Gynecologic Oncology. 31(4). e68–e68. 13 indexed citations
16.
Li, Yucong, Dong Wang, Jingshu Liu, et al.. (2020). <p>Baicalin Attenuates YAP Activity to Suppress Ovarian Cancer Stemness</p>. OncoTargets and Therapy. Volume 13. 7151–7163. 17 indexed citations
17.
18.
Wu, Xiaohua, Jianqing Zhu, Jun Wang, et al.. (2020). 820P Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC). Annals of Oncology. 31. S619–S620. 2 indexed citations
19.
Liu, Junmei, et al.. (2018). Advances in research of the nutritional value and health function of ovum of Rana chensinensis.. Shipin yanjiu yu kaifa. 39(11). 220–224. 3 indexed citations
20.
Zhang, Li & Qi Zhou. (2018). Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. European Journal of Pharmacology. 837. 64–71. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jing Yuan Breakdown of academic impact, for papers by Lina Gu Breakdown of academic impact, for papers by Keqiang Zhang Breakdown of academic impact, for papers by Yan Ding Breakdown of academic impact, for papers by Jiekai Yu Breakdown of academic impact, for papers by Rong Ma Breakdown of academic impact, for papers by Denglong Wu Breakdown of academic impact, for papers by Bingyin Shi Breakdown of academic impact, for papers by Jenq-Chang Lee
Rankless by CCL
2026